Simplified Chinese

English

Home page

Minhai Biologics Hosts an Innovative Vaccine Symposium, Focusing on the Cutting Edge of Therapeutic Vaccines for Myasthenia Gravis

Release date:

2025-08-14

Author:

Source:

Abstract

On July 31, Beijing Minhai Biotechnology Co., Ltd. successfully held an “Innovative Vaccine Technology Seminar” in the First Conference Room of its R&D Building, focusing on cutting-edge research into therapeutic vaccines for myasthenia gravis (MG). The event was attended by the company’s Executive Deputy General Manager, expert advisors, deputy general managers, production leaders, the general manager’s assistant, and more than 60 key R&D personnel. Professor Roger from the George Washington University School of Medicine was invited to deliver the keynote address, sharing the latest research findings and technological breakthroughs in this field. Professor Roger has devoted over thirty years to studying the pathogenesis and treatment of myasthenia gravis. He explained that MG is an antibody‑mediated autoimmune disorder whose core mechanism involves the immune system mistakenly attacking acetylcholine receptors at the neuromuscular junction, thereby blocking nerve signal transmission and causing muscle weakness. Currently, clinical management primarily relies on immunosuppressants and targeted antibodies; while these approaches can alleviate symptoms, they are associated with significant long-term side effects, high costs, and the inability to achieve a cure. In response to this unmet clinical need, Professor Roger’s team has innovatively developed a therapeutic vaccine based on proteins within the intramembrane region of the acetylcholine receptor. Animal studies have demonstrated that this vaccine can elicit a specific antibody response, delivering “threefold therapeutic benefits”: redirecting the antibody response from the extracellular domain to the intramembrane region, thus reducing the pathogenic antibodies’ attack on the neuromuscular junction; markedly diminishing antibody‑induced activation of the complement system, thereby mitigating immune‑mediated tissue damage; and inducing a shift in antibody subtypes, converting highly pathogenic IgG2b into non‑pathogenic variants. In rat models, after administration at an optimized dose, MG symptoms were completely suppressed, with protective effects sustained for six months following discontinuation of treatment and no apparent adverse effects—offering a novel approach toward curing MG. As a leading biopharmaceutical enterprise in China, Minhai Biotechnology has consistently placed “unmet clinical needs” at the heart of its R&D strategy. This seminar not only showcased the company’s forward‑looking initiatives in the vaccine field but also established a high‑level academic platform for advancing therapies for neuroimmune disorders. Looking ahead, Minhai Biotechnology will continue to ramp up R&D investment, accelerating the translation of innovative treatments from the laboratory into clinical practice, and contributing Chinese expertise to patients worldwide. Views: 910 Modified on August 5, 2025

7 month 31 On [date], Beijing Minhai Biotechnology Co., Ltd. successfully held [event] in the First Conference Room of the R&D Building. “ Innovative Vaccine Technology Lecture ” , focusing on myasthenia gravis ( MG ) Cutting-edge research on therapeutic vaccines. The company’s Executive Deputy General Manager, expert advisor, deputy general manager, head of production, assistant to the general manager, and more than 60 key R&D personnel attended. ， Professor Roger of the George Washington University School of Medicine was invited to deliver a keynote address, sharing the latest research findings and technological breakthroughs in the field.

Professor Roger has devoted more than thirty years to researching the pathogenesis and treatment of myasthenia gravis. He pointed out that, MG It is an antibody‑mediated autoimmune disease whose core pathogenic mechanism involves the immune system mistakenly attacking the acetylcholine receptors at the neuromuscular junction, thereby blocking neural signal transmission and resulting in muscle weakness. Currently, clinical management still relies primarily on immunosuppressants and targeted antibodies; although these can alleviate symptoms, they are associated with significant long-term adverse effects, high costs, and an inability to achieve a cure.

Addressing this unmet clinical need, Roger’s team has innovatively designed a therapeutic vaccine based on the intracellular domain of the acetylcholine receptor. Animal studies have demonstrated that this vaccine can elicit the production of antigen-specific antibodies, thereby achieving… “ Triple efficacy ” : Redirecting the antibody response from the extracellular region “ Redirect ” To the intramembrane domain, it reduces the attack of pathogenic antibodies on the neuromuscular junction; significantly decreases antibody‑mediated activation of the complement system, thereby mitigating immune‑mediated damage; and induces Antibody subtype Conversion, rendering it highly pathogenic IgG2b Converted to a non-pathogenic subtype. In a rat model, following administration at an optimized dose, MG Symptoms were completely suppressed, and the protective effect persisted for six months after discontinuation of the medication, with no obvious adverse effects observed, indicating a potential cure. MG It offers a completely new perspective.

As a leading biopharmaceutical company in China, Minhai Biologics has always placed “ Unmet clinical needs ” As a cornerstone of R&D, this lecture not only showcased the company’s forward-looking strategic positioning in the vaccine field but also established a high‑level academic platform for the treatment of neuroimmune diseases. Moving forward, Minhai Biologics will continue to ramp up its R&D investment, accelerate the translation of more innovative therapies from the laboratory into clinical practice, and contribute Chinese expertise to patients worldwide.

Keywords:

Minhai Biotechnology won first prize in the confined-space category of the inaugural Safety Production Competition.

Warm congratulations to Minhai Biotechnology on being awarded the Second Prize of the 2024 Beijing Science and Technology Progress Award.

Recommended Reading

Batch Release Status of the Company’s Products in 2026

The company's product 2026 annual batch issuance situation is as follows:

2026-07-23

Good News | Another Star Award! Minhai Biotechnology has once again been recognized as a “Five-Star Green Credit Enterprise” in Daxing District.

Recently, the Daxing District Bureau of Ecology and Environment completed the fifth round of corporate green credit rating for 2025 and officially released the “2025 Daxing District Green Credit Enterprise Directory.” Thanks to its robust environmental management system, consistent compliance performance, and outstanding achievements in energy conservation and carbon reduction, Minhai Biotechnology has once again been awarded the region’s highest “Five-Star Green Credit Enterprise” rating. The Daxing District’s corporate green credit assessment covers five major categories—environmental compliance, pollution control and emission reduction, low‑carbon circular economy, scientific management, and social contribution—comprising a total of 30 sub‑indicators. With stringent standards and comprehensive evaluation, the program employs dynamic review and a veto‑based mechanism, with the Five‑Star rating representing the highest level of ecological credit in the district.

2026-07-15

Good News | The Party Branch of Minhai Biotechnology has been awarded the “Two Excellences and One Pioneer” honor in Beijing’s emerging sectors, as well as a park‑level commendation.

Recently, Beijing held a grand commendation conference for the “Two Excellences and One Pioneer” initiative in emerging sectors. The “Two New” Working Committee of the CPC Beijing Municipal Committee recognized outstanding Communist Party members, exemplary Party affairs workers, and advanced primary-level Party organizations across the city’s emerging fields. The Party branch of Beijing Minhai Biotechnology Co., Ltd. was honored as an advanced primary-level Party organization in Beijing’s emerging sectors. Wu Chengyu, the branch secretary, attended the ceremony in person to receive the award. At the event, the Party flag flew proudly amid a solemn atmosphere, and the awardees, adorned with honor ribbons and holding certificates and medals, jointly witnessed this prestigious municipal recognition. This designation as an advanced primary-level Party organization at the municipal level represents the “Two New” Working Committee of the Municipal Party Committee’s high appraisal of the Minhai Biotechnology Party branch.

2026-07-09

Online Customer Service

Telephone

400 189 9806

Contact Information

Customer Service Hotline

4001899806

Phone number

010-59613600

Official Website

http://www.biominhai.com

Company Address

No. 35 Simiao Road and No. 25 Tianfu Street, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing

WeChat Official Account

Business license

Website Development: China Enterprise Dynamics

Beijing

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.